IGF-1 LR3

IGF-1 stands for insulin like growth factor 1. The natural one is a chain of 70 of the building blocks that proteins are made from, and it is the molecule your own liver makes. IGF-1 LR3 is a lab made version of it, and it is not the same shape. It runs to 83 building blocks, with the one at position 3 swapped from glutamic acid to arginine and a 13 unit extension added onto the front, 11 of those units taken from a pig growth hormone sequence and two more acting as a joint. Francis and colleagues described it in 1992, at a research body called CSIRO in Adelaide. Every one of those changes was aimed at loosening its grip on the carrier proteins that normally hold insulin like growth factor 1 in the blood. It began as a construct for growing the protein in a bacterium called E. coli, and today it sells as a supplement for feeding cells in a laboratory dish, on pages carrying a warning that the product is not for human or veterinary use. A 2006 paper describes it as specifically engineered for use in producing biological drug proteins in mammalian cells. Do not over-read that, as the article puts it: it came out of a programme trying to make a therapeutic drug, and it went through rats, guinea pigs, pigs and sheep as a drug candidate. It failed to become one. It was not designed to avoid being one.

Skip the gland and inject the signal. That is the pitch. Most insulin like growth factor 1 in the blood does not travel alone. It rides in a package of three, with a carrier protein called insulin like growth factor binding protein 3 and a third piece called the acid labile subunit, and that package is what stretches out how long the hormone stays in the blood. LR3 was engineered not to join that package. Much reduced grip on those carrier proteins is the whole premise, and, as the article puts it, also the problem. Which way that loosened grip pushes growth turns out to depend on the animal. In 150 gram rats dosed under the skin for seven days, continuous infusion made LR3 1.5 to 2 times more potent than the native hormone for body weight gain, the weights of the internal organs and how efficiently feed was used, and that advantage was much reduced under once daily injection, which is how the compound actually gets used. In pigs the same class of molecule went the other way, and the paper that ran them states as settled background that analogues binding poorly to those carrier proteins stimulate growth in the rat and inhibit growth in the pig. Which of the two a human resembles is not a small question, and the article's author found no resolution of it.

People buy it for muscle. The claim that runs through community writing is that injecting it into a particular muscle grows that muscle, and the article's author found no study testing an injection into a muscle for localised muscle growth in any species. The one site specific study with a growth endpoint was negative: long R3 insulin like growth factor 1 was infused into an artery feeding a patch of skin in six conscious sheep for four hours, which raised local blood flow, oxygen consumption and amino acid uptake, and the paper reports no effect on the number of dividing cells in the bulbs of the wool follicles. Across the rest of the animal record, what got heavier was gut, kidney, spleen, adrenal glands and heart. In guinea pigs given a seven day infusion at about 343 micrograms for every kilogram of body weight per day, the adrenals, gut, kidneys and spleen rose as a share of body weight and the authors state overall growth was not stimulated. In rats held at 100, 78, 56 or 33 percent of free feeding and infused at about 893 micrograms per kilogram per day, body weight ran 3 to 8 percent higher and more nitrogen was retained at every level of intake, both at P below 0.001, and muscle protein was not conserved. Skeletal muscle is the one thing it is bought for and the one thing that record is thinnest on.

The expensive mistake is borrowing Increlex's file. Mecasermin, sold as Increlex, is an approved medicine with real trials, a real label, real low blood sugar numbers and a real cancer warning, and that document gets waved over a molecule that began as a construct for growing protein in a bacterium. It is a different substance and none of it transfers. The second mistake is the half life. LR3 was built specifically so that it would not join the package that keeps insulin like growth factor 1 in the blood, and it is then sold as long acting. That is taking the lid off the pot to make the water boil faster and quoting the time it took with the lid on. The third is the amount. The roughly 20 to 100 micrograms a day that circulates has no derivation the article's author could find anywhere: no allometric scaling from a named animal study, no dose ranging work, no pharmacokinetic anchor. Per kilogram it is small rather than large, about 0.25 to 1.25 micrograms for every kilogram of body weight per day in an 80 kilogram adult, and every published dose sits above it, but sitting under a pig dose is not a safety finding, because I could not find a measurement in a person at any dose.

Low blood sugar is the documented danger, and unusually for this reference it is documented in this molecule rather than in a relative. In pigs given single injections of 20 and 50 micrograms for every kilogram of body weight, the low binding variants, LR3 among them, were consistently 2 to 3 times more potent than the native hormone at driving blood glucose down to its lowest point, and adding the suppression up across four hours showed roughly a 4 to 8 fold increase in the extent of the low blood sugar. The largest fall measured in the pig was 4.8 millimoles per litre. The same authors note that these variants clear faster than the native hormone and yet suppress glucose harder and for longer. Short acting in the blood, long acting on blood sugar. Two things get attached to this and should not be. The first is monkeys. That paper's title names marmoset monkeys, and the marmoset arm is real, but those animals received only insulin like growth factor 1 and a second variant written des(1-3)IGF-I, so LR3 was in the pig arm alone. If you see LR3 low blood sugar attributed to monkeys, that experiment was not run. The second is Increlex, the approved drug, which is where every human low blood sugar number in this area comes from: roughly 42 percent of subjects had low blood sugar at least once, with 5 cases of severe low blood sugar and 4 seizures caused by it, and that label is contraindicated in active or suspected cancer, with section 5.7 recording cancers reported after marketing in children given it, more often at doses above those recommended. That is a different molecule and none of it is a measurement of this one. There is no published measurement of blood glucose in a human given IGF-1 LR3, at any dose, by any route. The article's author also found no cancer study, no repeat dose toxicity study and no genetic damage study of LR3 in any species, so the empty record here means untested rather than clean. The World Anti-Doping Agency prohibits it at all times under S2, peptide hormones, growth factors, related substances and mimetics, and the article prints no sub-section number because its author could not open the 2026 Prohibited List itself.